Press Release: Novartis presents new data on -2-

information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.

References

1. Day JW, et al. Lancet Neurol. 2021; 20:284--93.

2. Mendell JR, et al. N Engl J Med. 2017; 377:1713--22.

3. Al-Zaidy SA, et al. J Neuromuscul Dis. 2019; 6:307--17.

4. Mercuri E, et al. Lancet Neurol. 2021; 20:832--41.

5. Strauss K, et al. Nat Med. 2022; 28:1381--9.

6. Strauss K, et al. Nat Med. 2022; 28:1390--7.

7. Data on File. Novartis AG, 2023.

8. Anderton RS and Mastaglia FL. Expert Rev Neurother. 2015;15(8):895--908.

9. Finkel RS, McDermott MP, Kaufmann P. et al. Neurology. 2014;83(9):810--7.

10. Sugarman EA, Nagan N, Zhu H, et al. Eur J Hum Genet. 2012;20(1):27--32.

11. Lorson CL, Rindt H, Shababi M. Hum Mol Genet. 2010;(15):111--8.

12. Verhaart IEC, Robertson A, Wilson IJ, et al. Orphanet J Rare Dis. 2017;4;12(1):124.

13. Feldkötter M, et al. Am J Hum Genet. 2002;70:358--68.

14. Darras BT, Finkel RS. "Natural history of spinal muscular atrophy." In: Sumner CJ, Paushkin S, Ko CP, eds. Spinal Muscular Atrophy: Disease Mechanisms and Therapy. (2nd ed. London, UK: Academic Press/Elsevier; 2017. Pp. 399--421.

15. Soler--Botija C, et al. Brain. 2002;125(7):1624--1634.

16. Glascock J, et al. J Neuromuscul Dis. 2018;5:145--158.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Richard Jarvis +41 79 584 2326 Julie Masow +1 862 579 8456

Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414

Anna Schäfers +41 79 801 7267 Marlena Abdinoor +1 617 335 9525

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line:

+41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Isabella Zinck +41 61 324 7188 Jonathan Graham +1 201 602 9921

Nicole Zinsli-Somm +41 61 324 3809 Parag Mahanti +1 973 876 4912

Imke Kappes +41 61 324 8269

(END) Dow Jones Newswires

March 04, 2024 01:15 ET (06:15 GMT)